|
1
|
Chesi M and Bergsagel PL: Molecular
pathogenesis of multiple myeloma: Basic and clinical updates. Int J
Hematol. 97:313–323. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fonseca R, Blood EA, Oken MM, Kyle RA,
Dewald GW, Bailey RJ, Van Wier SA, Henderson KJ, Hoyer JD,
Harrington D, et al: Myeloma and the t(11;14)(q13;q32); evidence
for a biologically defined unique subset of patients. Blood.
99:3735–3741. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hoyer JD, Hanson CA, Fonseca R, Greipp PR,
Dewald GW and Kurtin PJ: The (11;14)(q13;q32) translocation in
multiple myeloma. A morphologic and immunohistochemical study. Am J
Clin Pathol. 113:831–837. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robillard N, Avet-Loiseau H, Garand R,
Moreau P, Pineau D, Rapp MJ, Harousseau JL and Bataille R: CD20 is
associated with a small mature plasma cell morphology and t(11;14)
in multiple myeloma. Blood. 102:1070–1071. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hamadeh F, MacNamara SP, Aguilera NS,
Swerdlow SH and Cook JR: MYD88 L265P mutation analysis helps define
nodal lymphoplasmacytic lymphoma. Mod Pathol. 28:564–574. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Moreau P, Facon T, Leleu X, Morineau N,
Huyghe P, Harousseau JL, Bataille R and Avet-Loiseau H: Intergroupe
Francophone du Myélome: Recurrent 14q32 translocations determine
the prognosis of multiple myeloma, especially in patients receiving
intensive chemotherapy. Blood. 100:1579–1583. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kaufman GP, Gertz MA, Dispenzieri A, Lacy
MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Lust JA, Russell S, et
al: Impact of cytogenetic classification on outcomes following
early high-dose therapy in multiple myeloma. Leukemia. 30:633–639.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moreau P, Voillat L, Benboukher L, Mathiot
C, Dumontet C, Robillard N, Hérault O, Garnache F, Garand R,
Varoqueaux N, et al: IFM group: Rituximab in CD20 positive multiple
myeloma. Leukemia. 21:835–836. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Treon SP, Pilarski LM, Belch AR, Kelliher
A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ,
Ellman L, et al: CD20-directed serotherapy in patients with
multiple myeloma: Biologic considerations and therapeutic
applications. J Immunother. 25:72–81. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bergua JM, Cabrera C, Arteta EG and Prieto
J: Rituximab in CD20 positive multiple myeloma. Leukemia.
22:1082–1083. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Segeren CM, Sonneveld P, van der Holt B,
Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW,
Fibbe WE, Löwenberg B, et al: Vincristine, doxorubicin and
dexamethasone (VAD) administered as rapid intravenous infusion for
first-line treatment in untreated multiple myeloma. Br J Haematol.
105:127–130. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kumar S, Kaufman J, Gasparetto C, Mikhael
J, Vij R, Pegourie B, et al: Efficacy of venetoclax as targeted
therapy for relapsed/refractory t(11;14) multiple myeloma. Blood.
2017.blood-2017-06-788786. View Article : Google Scholar
|
